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Abstract 
Background: Previous studies on high grade sarcomas using mass spectrometry imaging showed proteasome acti‑
vator complex subunit 1 (PSME1) to be associated with poor survival in soft tissue sarcoma patients. PSME1 is involved 
in immunoproteasome assembly for generating tumor antigens presented by MHC class I molecules. In this study, 
we aimed to validate PSME1 as a prognostic biomarker in an independent and larger series of soft tissue sarcomas by 
immunohistochemistry.
Methods: Tissue microarrays containing leiomyosarcomas (n = 34), myxofibrosarcomas (n = 14), undifferentiated 
pleomorphic sarcomas (n = 15), undifferentiated spindle cell sarcomas (n = 4), pleomorphic liposarcomas (n = 4), 
pleomorphic rhabdomyosarcomas (n = 2), and uterine leiomyomas (n = 7) were analyzed for protein expression of 
PSME1 using immunohistochemistry. Survival times were compared between high and low expression groups using 
Kaplan–Meier analysis. Cox regression models as multivariate analysis were performed to evaluate whether the asso‑
ciations were independent of other important clinical covariates.
Results: PSME1 expression was variable among soft tissue sarcomas. In leiomyosarcomas, high expression was 
associated with overall poor survival (p = 0.034), decreased metastasis‑free survival (p = 0.002) and lower event‑free 
survival (p = 0.007). Using multivariate analysis, the association between PSME1 expression and metastasis‑free sur‑
vival was still significant (p = 0.025) and independent of the histological grade.
Conclusions: High expression of PSME1 is associated with poor metastasis‑free survival in soft tissue leiomyosar‑
coma patients, and might be used as an independent prognostic biomarker.
Keywords: Proteasome activator complex subunit 1, Prognostic biomarker, Sarcoma, Leiomyosarcoma, Soft tissue 
sarcoma, Immunohistochemistry
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Background
Soft tissue sarcomas are a heterogeneous group of rare 
malignancies often having poor outcome [1]. Soft tis-
sue sarcomas constitute less than 1  % of all cancers [1] 
while there are more than 50 histological subtypes with 
sometimes overlapping histological features [2]. Distinc-
tion is essential as subtypes differ in biological behaviour 
and sensitivity to chemotherapy, and as such an adequate 
histological diagnosis, is crucial for clinical decision mak-
ing [3]. Fifty-six percent of soft tissue sarcomas present 
as localized disease at the time of diagnosis, and surgery 
is the mainstay of treatment, sometimes combined with 
radiotherapy or chemotherapy [4].
From the molecular point of view, soft tissue sarco-
mas can be distinguished into two categories. The first 
class includes sarcomas with a simple genome, in which 
recurrent translocations, amplifications or specific muta-
tions can be found. The second class includes sarcomas 
with a complex genome, characterized by a multitude 
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of chromosomal alterations and genomic instability, 
often reflected by pleomorphic histological features [3]. 
This group includes high grade leiomyosarcoma, myxo-
fibrosarcoma, undifferentiated pleomorphic sarcoma, 
undifferentiated spindle cell sarcoma, pleomorphic lipo-
sarcoma, and pleomorphic rhabdomyosarcoma.
Leiomyosarcomas constitute 5–10  % of all soft tissue 
sarcomas, displaying smooth-muscle differentiation [1]. 
Studies showed for leiomyosarcoma that the metastasis-
free 5-year survival rate is about 60  % [5]. Histological 
grade is the most important prognostic factor for most 
soft tissue sarcomas. By using FNCLCC grading system, 
which is the most widely used 3-grade system, soft tis-
sue sarcomas are divided into low, intermediate and high 
grade based on the sum score of three histologic param-
eters including tumor differentiation, mitotic count and 
tumor necrosis. About 65  % of leiomyosarcomas are 
reported to have high-grade areas [6]. High grade leio-
myosarcomas often have poor patient outcome [4]. Until 
now, the genetics and pathology of leiomyosarcomas are 
not completely understood and as they have a complex 
genome, no molecular diagnostic tests or specific thera-
peutic targets are available. Hence, there is a strong need 
for new molecular markers that can aid in the stratifica-
tion of leiomyosarcomas patients with respect to their 
disease outcome.
In a previous study, we used imaging mass spectrome-
try to compare these soft tissue sarcomas with a complex 
genome. A panel of protein signatures that could distin-
guish between different subtypes, or were associated to 
patient survival were discovered [7]. Among them, pro-
teasome activator complex subunit 1 (PSME1) was found 
indicative of poor survival in soft tissue sarcomas. PSME1 
(also known as REGalpha and PA28A), is a multicatalytic 
proteinase complex, implicated in immunoproteasome 
assembly and required for efficient antigen processing 
[8]. Intriguingly, PSME1 was also found to associate with 
diagnosis or prognosis in other tumor types, e.g. prostate 
cancer [9], breast cancer [10] and ovarian cancer [11, 12].
In this study, we used tissue microarrays of soft tissue 
sarcomas with complex genomes, to evaluate whether 
PSME1 expression can predict clinical outcome in soft 
tissue sarcomas, especially leiomyosarcomas.
Methods
Tissue microarrays
Tissue microarrays were previously constructed from 
paraffin embedded formalin fixed tissues using a semi-
automated TMA apparatus (TMA Master; 3D Histech, 
Budapest, Hungary) [13]. Clinicopathological details 
were described previously [14]. In brief, analysed sam-
ples include 34 leiomyosarcomas, 14 myxofibrosarco-
mas, 15 undifferentiated pleomorphic sarcomas, four 
undifferentiated spindle cell sarcomas, four pleomorphic 
liposarcomas, two pleomorphic rhabdomyosarcomas, 
and seven uterine leiomyomas. Clinicopathological data 
for the leiomyosarcomas, as described previously [14], 
are summarized in Additional file 1: Table S1. All tumor 
samples are present at least in triplicates with a diameter 
of 1.5  mm (a surface area of around 1.767  mm2). Cores 
from colon, liver, placenta, prostate, skin, and tonsil were 
included for control and orientation purposes. Four 
micrometre thick sections were transferred by using a 
tape-transfer system to coated glass slides for analysis.
The histological diagnosis of all samples was confirmed 
by reviewing the hematoxylin and eosin—stained slides 
by expert pathologist (J. V. M. G. B.). Malignant tumors 
were graded according to the FNCLCC (French Fédéra-
tion Nationale des Centres de Lutte Contre le Cancer) 
grading system [1]. All samples were handled according 
to the Dutch code of proper secondary use of human 
material as accorded by the Dutch society of pathology 
(Federa). The samples were handled in a coded manner. 
All study methods were approved by the LUMC ethical 
board (B16.025).
PSME1 immunohistochemistry
Four micrometre thick sections were dried overnight 
at 37   °C. Immunohistochemistry was performed using 
anti-PSME1 antibody (clone [EPR10968(B)], abcam, 
Cambridge, UK) according to protocols described pre-
viously [15]. Briefly, slides underwent deparaffinization, 
blocking of endogenous peroxidase, antigen retrieval 
(10  min microwave in citrate, pH 6.0), pre-incubation, 
and addition of the primary antibody in a dilution of 
1:1500 overnight. Next, slides were incubated with Poly-
HRP-GAM/R/R [Immunologic BV, Duiven, The Nether-
lands (DPVO110HRP)], visualized with DAB+Substrate 
Chromogen System (DAKO, Heverlee, Belgium) and 
counterstained with hematoxylin. Colon tissue was used 
as a positive control. As a negative control slides were 
incubated with PBS/1  % BSA instead of the primary 
antibody.
Scoring of immunohistochemistry
Slides were scored independently by two observers 
(J.V.M.G.B and A.H.G.C) as described previously [16]. 
In brief, staining intensity (0, absent; 1, weak; 2, moder-
ate; 3, strong) and percentage of positive tumor cells (0, 
0 %; 1, 1–24 %; 2, 25–49 %; 3, 50–74 %; 4, 75–100 %) were 
assessed. Afterwards, scores of staining intensity and 
percentage of positive tumor cells were added to obtain 
the sum score; for later statistical analysis, the average 
sum score was calculated over all cores belonging to the 
same tumor. Proteasomes are present both in the nucleus 
as well as in the cytoplasm of eukaryotic cells, although 
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their relative abundance within these compartments 
can be highly variable [8, 17–20]. We therefore evalu-
ated cytoplasmic and nuclear staining separately. Cores 
in which tissue was lost or with not enough tumor area 
were excluded from the analysis. Cores with differences 
on sum score from two observers more than two were re-
evaluated to reach consensus.
Statistical analysis
Only primary tumour samples were used in statistical 
analysis. First, the distribution of sum score data was 
evaluated by Shapiro–Wilk normality test. As this test 
showed that the score data was not normally distrib-
uted, nonparametric Spearman correlation coefficient 
was used as a measure of the statistical dependence 
between the histological grades and PSME1 expression. 
Further statistical two-group comparisons between con-
trols (uterine leiomyoma) and the different histological 
grades of soft tissue sarcomas were calculated by Dunn’s 
multiple-comparison test. Spearman correlation was per-
formed in R environment (R Foundation for statistical 
Computing, Vienna, Austria), scatter plots and Dunn’s 
test results were generated in GraphPad Prism version 
6.00 for Windows (GraphPad Software, La Jolla, Califor-
nia, USA, http://www.graphpad.com). All two-sided p 
values equal or lower than 0.05 were considered statisti-
cally significant.
For survival analysis, patients were dichotomized into 
two groups. We dichotomized leiomyosarcoma patients 
into high and low expression groups according to the 
sum scores of immunohistochemistry, for which we 
chose the cut-off at the 3rd quartile—Experience shows 
that molecular subgroups are usually found in 10–25  % 
of the patients (e.g. HER2 overexpression [21], KRAS 
mutation [22]). Differences in overall survival, metasta-
sis-free survival and event-free survival between these 
groups were investigated using Kaplan–Meier curves and 
the log-rank test. Independent variables predicting sur-
vival were evaluated in a multivariable model using Cox 
Regression analyses. Survival analysis was performed in 
R environment (R Foundation for statistical Comput-
ing, Vienna, Austria) using Survival package and all two-
sided p values lower or equal than 0.05 were considered 
statistically significant.
Results
Variable nuclear and cytoplasmic expression of PSME1 
in soft tissue sarcomas
In soft tissue sarcomas, PSME1 protein expression was 
found in the majority of the cases, both in the nucleus as 
well as in the cytoplasm. In contrast, expression in benign 
leiomyoma was low or absent (Fig. 1a, b). Representative 
images of immunohistochemistry are shown in Fig. 2.
Increased expression of PSME1 with increasing histological 
grade in leiomyosarcomas
The leiomyosarcoma subgroup was large enough to ana-
lyse a possible correlation with histological grade. Indeed, 
while expression was low to absent in uterine leiomyoma, 
expression gradually increased with increasing histologi-
cal grade in both nucleus (poverall = 0.000357) and cyto-
plasm (poverall  =  0.00045) in leiomyosarcomas (Fig.  1c, 
d). Further statistical two groups comparisons between 
control and any histological grade by Dunn’s multiple 
comparisons test showed that both nuclear and cytoplas-
mic staining significantly differed in uterine leiomyomas 
versus leiomyosarcomas grade 2 (p ≤  0.05) and uterine 
leiomyomas versus leiomyosarcomas grade 3 (p ≤ 0.01).
High nuclear expression of PSME1 predicts poor outcome 
in leiomyosarcoma patients
To investigate a possible correlation of PSME1 expres-
sion with clinical outcome, leiomyosarcoma patients 
were dichotomized into high and low PSME1 expression 
groups according to the sum scores of immunohisto-
chemistry. High PSME1 expression was associated with 
poor overall survival (p =  0.034), decreased metastasis-
free survival (p  =  0.002) and lower event-free survival 
(p = 0.007) (Fig. 3).
High nuclear expression of PSME1 as an independent 
prognostic factor in leiomyosarcoma patients
Using multivariable Cox Regression analyses including 
clinically relevant co-factors such as histological grade, 
age and gender, we showed that high nuclear expression 
of PSME1 was independently associated with metastasis-
free survival (p = 0.03) (Table 1). The independent pre-
dictive power of nuclear PSME1 expression for overall 
and event-free survival was at the border of significance 
(p = 0.07) (Table 1).
Discussion
Using imaging mass spectrometry we previously identi-
fied PSME1 as a prognostic biomarker indicating poor 
survival in soft tissue sarcoma patients [7]. Imaging mass 
spectrometry is a sensitive discovery tool (zepto-molar 
sensitivity [23]) enabling the detection of hundreds 
of molecules directly from tissue [24, 25]. To further 
explore the prognostic value of PSME1 we analysed 
PSME1 expression in a larger, independent set of soft 
tissue sarcomas using immunohistochemistry on tis-
sue microarrays. PSME1 (or PA28A) encodes a subunit 
of the proteasome system, which is a major source for 
generation of tumor antigens presented by MHC class I 
molecules [26, 27]. Escape of immune response is one of 
the hallmarks of cancer [28]. In addition, elevated pro-
teasome activity in tumor cells has been described to 
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influence transcription factors involved in cell survival or 
apoptosis [29, 30]. Novel strategies using the proteasome 
have been proposed for cancer treatment for example by 
alternating the NAD+/NADH ratio to change kinetics of 
proteasomal degradation [30] or inhibiting proteasome 
to induce apoptosis [31–34].
PSME1 is expressed in many different cell types, 
especially antigen presenting cells, and its expression 
can be controlled by interferon gamma. Both chemo-
therapy and TNF-alpha may induce a local inflamma-
tory reaction within the tumor microenvironment and 
therefore may influence expression of PSME1. It is of 
interest that all sarcoma subtypes included in our study 
expressed PSME1 to a variable extent, while neoadjuvant 
chemotherapy or treatment with interferon gamma is not 
standard practice in our hospital. As far as clinical data 
were available, only four patients received preoperative 
chemotherapy or TNF-alpha, and expression levels were 
not significantly different. In the control group, consist-
ing of uterine leiomyomas, expression was low to absent, 
both in the nucleus as well as in the cytoplasm.
High PSME1 expression was also described in other 
tumors. For example, increased PSME1 expression 
was also found in primary and metastatic human pros-
tate cancer and was suggested as a potential target for 
therapeutic intervention [9]. PSME1 was previously 
also detected using imaging mass spectrometry in other 
tumors: Dekker et  al. detected PSME1 as a marker of 
Fig. 1 Summary of PSME1 immunohistochemistry results. Variable expression of PSME1 both in the cytoplasm (a) as well as in the nucleus (b) in 
soft tissue sarcomas, while expression in uterine leiomyoma (LM; control) is low. LMS leiomyosarcomas, LPS pleomorphic liposarcomas, MFS myxofi‑
brosarcomas, RMS pleomorphic rhabdomyosarcomas, UPS undifferentiated pleomorphic sarcomas, and USCS undifferentiated spindle cell sarcomas. 
In leiomyosarcomas, both cytoplasmic (c) and nuclear (d) expression increased with increasing histological grade (p = 0.00045 and p = 0.000357). 
In addition, both cytoplasmic and nuclear expression of PSME1 was significantly higher in intermediate and high grade leiomyosarcomas as com‑
pared to uterine leiomyomas (p ≤ 0.05/p ≤ 0.01). All score data for each group were presented in mean ± SD
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stromal activation in breast cancer [10]. Previous studies 
also showed that PSME1 could be a molecular signature 
to discriminate between benign and malignant ovar-
ian tumors [11, 35], and an early diagnosis and tumor-
relapse biomarker [12]. Zhang et al. detected PSME1 as 
a tumor marker in human oesophageal squamous cell 
carcinoma [36]. The proteasome can be present in the 
cytoplasm as well as in the nucleus of all eukaryotic cells, 
although their distribution and function can be variable 
[17]. We here show that in soft tissue sarcomas with a 
complex genome, PSME1 is expressed both in the cyto-
plasm and in the nucleus. Proteasome-dependent pro-
tein degradation is important in the cytoplasm for MHC 
class 1 antigen presentation [8]. In the nucleus, PSME1 
plays an important role in maintaining the nuclear 
function including gene expression and cell proliferation 
[19, 37].
To further evaluate its clinical relevance, we ana-
lysed the largest subgroup, comprising 34 leiomyosarco-
mas of different histological grade, in more detail. Both 
nuclear as well as cytoplasmic expression of PSME1 sig-
nificantly increased with increasing histological grade. 
Moreover, high nuclear expression of PSME1 was sig-
nificantly associated to poor outcome (overall survival, 
metastasis-free survival and event-free survival) in leio-
myosarcoma patients, although the patient cohort is 
rather small (n  =  34). In multivariate analysis only the 
association with decreased metastasis-free survival was 
independent of histological grade, while an independ-
ent association to poor overall survival and decreased 
Fig. 2 Representative images of immunohistochemistry of PSME1. a and b are two leiomyosarcoma (LMS) samples with high expression of PSME1. 
c A uterine leiomyoma (LM) control sample with low expression of PSME1. Images in red squares are the overviews of expression the tissue microar‑
ray cores for respective samples
Fig. 3 Kaplan–Meier survival plots of PSME1. Kaplan–Meier plots comparing the different survival data of leiomyosarcoma patients with respect to 
a high and low nuclear expression of PSME1 (cut‑off: 3rd quartile). High nuclear expression of PSME1 in leiomyosarcoma was significantly associated 
with decreased overall survival, metastasis‑free survival and event‑free survival (log‑rank test; p ≤ 0.05)
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event-free survival was at the border of significance. 
Although PMSE1 expression is a promising biomarker, 
our results need to be validated in an independent cohort 
of leiomyosarcomas.
In summary, we found elevated expression of the protea-
some subunit PSME1 in leiomyosarcomas compared to 
control tissues, and an association of the expression with 
increasing histological grade in leiomyosarcoma. Moreover, 
high nuclear PSME1 expression was found to be an inde-
pendent predictor of metastasis-free survival in leiomyo-
sarcoma patients. Our results suggest that the expression 
of proteasome subunits such as PSME1 could be taken into 
account for leiomyosarcoma patients when considering 
immunotherapeutic strategies in these tumors [38].
Conclusions
We show variable expression of PSME1 in different soft 
tissue sarcoma subtypes with complex genomes. Our 
results showed that high nuclear expression of protea-
some activator complex subunit 1 is an independent 
poor prognostic factor in leiomyosarcomas, which sug-
gests that the proteasome could be exploited as a possible 
novel target for the treatment of leiomyosarcomas.
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Table 1 Results of multivariable analysis of factors influencing survival
* p value reaches statistically significant level (p ≤ 0.05)
Clinical association Variable Hazards ratio 95 % Confidence interval p value
Metastasis‑free survival
 PSME1 high nuclear expression 3.685 1.177–11.541 0.025*
 Histological grade 1.831 0.710–4.723 0.211
 Age 0.974 0.932–1.017 0.225
 Gender (M) 0.377 0.070–2.039 0.257
Event‑free survival
 PSME1 high nuclear expression 2.667 0.919–7.743 0.071
 Histological grade 2.216 0.882–5.569 0.090
 Age 0.975 0.937–1.015 0.215
 Gender (M) 0.339 0.068–1.695 0.188
Overall survival
 PSME1 high nuclear expression 2.612 0.916–7.448 0.072
 Histological grade 2.552 0.953–6.837 0.062
 Age 1.005 0.972–1.039 0.758
 Gender (M) 2.071 0.660–6.502 0.212
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